ResMed Statistics

Total Valuation

ResMed has a market cap or net worth of EUR 32.06 billion. The enterprise value is 31.97 billion.

Market Cap	32.06B
Enterprise Value	31.97B

Important Dates

The next estimated earnings date is Friday, August 1, 2025.

Earnings Date	Aug 1, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	146.37M
Shares Outstanding	n/a
Shares Change (YoY)	-0.07%
Shares Change (QoQ)	-0.18%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	145.44M

Valuation Ratios

The trailing PE ratio is 26.38 and the forward PE ratio is 25.10.

PE Ratio	26.38
Forward PE	25.10
PS Ratio	6.90
PB Ratio	6.25
P/TBV Ratio	15.28
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 20.61, with an EV/FCF ratio of 22.02.

EV / Earnings	26.31
EV / Sales	7.45
EV / EBITDA	20.61
EV / EBIT	23.15
EV / FCF	22.02

Financial Position

The company has a current ratio of 3.41, with a Debt / Equity ratio of 0.15.

Current Ratio	3.41
Quick Ratio	2.06
Debt / Equity	0.15
Debt / EBITDA	0.46
Debt / FCF	0.54
Interest Coverage	139.28

Financial Efficiency

Return on equity (ROE) is 25.81% and return on invested capital (ROIC) is 16.54%.

Return on Equity (ROE)	25.81%
Return on Assets (ROA)	14.01%
Return on Invested Capital (ROIC)	16.54%
Return on Capital Employed (ROCE)	24.33%
Revenue Per Employee	465,523
Profits Per Employee	121,746
Employee Count	9,980
Asset Turnover	0.70
Inventory Turnover	2.09

Taxes

In the past 12 months, ResMed has paid 244.24 million in taxes.

Income Tax	244.24M
Effective Tax Rate	16.74%

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	n/a
200-Day Moving Average	n/a
Relative Strength Index (RSI)	62.88
Average Volume (20 Days)	0

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	9.62

Income Statement

In the last 12 months, ResMed had revenue of EUR 4.65 billion and earned 1.22 billion in profits. Earnings per share was 8.24.

Revenue	4.65B
Gross Profit	2.76B
Operating Income	1.49B
Pretax Income	1.46B
Net Income	1.22B
EBITDA	1.63B
EBIT	1.49B
Earnings Per Share (EPS)	8.24

Full Income Statement

Balance Sheet

The company has 874.17 million in cash and 776.96 million in debt, giving a net cash position of 97.21 million.

Cash & Cash Equivalents	874.17M
Total Debt	776.96M
Net Cash	97.21M
Net Cash Per Share	n/a
Equity (Book Value)	5.13B
Book Value Per Share	35.00
Working Capital	2.10B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 1.53 billion and capital expenditures -77.87 million, giving a free cash flow of 1.45 billion.

Operating Cash Flow	1.53B
Capital Expenditures	-77.87M
Free Cash Flow	1.45B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 59.37%, with operating and profit margins of 32.10% and 26.15%.

Gross Margin	59.37%
Operating Margin	32.10%
Pretax Margin	31.41%
Profit Margin	26.15%
EBITDA Margin	35.14%
EBIT Margin	32.10%
FCF Margin	31.24%

Dividends & Yields

ResMed does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	23.14%
Buyback Yield	0.07%
Shareholder Yield	n/a
Earnings Yield	3.79%
FCF Yield	4.53%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

ResMed has an Altman Z-Score of 12.61 and a Piotroski F-Score of 8.

Altman Z-Score	12.61
Piotroski F-Score	8